Integration of multiple immune-associated biomarkers facilitates classification of solid tumors by primary immune escape mode and prediction of patient outcomes | SOCIETY FOR IMMUNOTHERAPY OF CANCER SITC 2022 | 2022 | society-for-immunotherapy-of-cancer-sitc-2022 | comprehensive-genomic-and-immune-profiling | non-small-cell-lung-cancer | cancer-testis-antigen-burden cell-proliferation-signature pd-l1-ihc tumor-immunogenic-signature tumor-mutational-burden | 2022 |
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma | Journal for ImmunoTherapy of Cancer | 2022 | journal-for-immunotherapy-of-cancer | rnaseq | renal-cell-carcinoma | immune-profile | 2022 |
Sensitivity and concordance of CD274(PD-L1) expression by RNA sequencing (RNA-seq) in comparison with three PD-L1 immunohistochemistry methods in head and neck squamous cell carcinoma (HNSCC) | SOCIETY FOR IMMUNOTHERAPY OF CANCER SITC 2022 | 2022 | society-for-immunotherapy-of-cancer-sitc-2022 | rnaseq | solid-tumors | immune-profile | 2022 |
The immune expression landscape of solid tumors with tertiary lymphoid structures | SOCIETY FOR IMMUNOTHERAPY OF CANCER SITC 2022 | 2022 | society-for-immunotherapy-of-cancer-sitc-2022 | pd-l1-ihc rnaseq | solid-tumors | immune-profile pd-l1-ihc | 2022 |
Comprehensive genomic and immune profiling of non-small cell lung cancer brain metastases reveals low tumor inflammation and elevated cancer testis antigen burden | Society for NeuroOncology | 2022 | society-for-neurooncology | dna-seq rnaseq | non-small-cell-lung-cancer | immune-profile mutational-profile | 2022 |
Combined Low-pass Whole Genome and Targeted Sequencing Identifies Causative Mutations and Associated Genomic Scarring Indicative of Homologous Recombination Deficiency | 2022 AMP Annual Meeting | 2022 | 2022-amp-annual-meeting | oa | solid-tumors | | 2022 |
Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC) | American Society of Clinical Oncology | 2022 | american-society-of-clinical-oncology | dna-seq msi pd-l1-ihc rnaseq tmb | non-small-cell-lung-cancer | clinical-decision-making clinical-utility pd-l1 | 2022 |
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy | Cancer Treatment Reviews | 2022 | cancer-treatment-reviews | pd-l1-ihc | solid-tumors | ctla-4 pd-l1 | 2022 |
Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance | 2022 ASCO Annual Meeting | 2022 | 2022-asco-annual-meeting | pd-l1-ihc rnaseq | solid-tumors | ctla-4 lag3 msi pd-l1 tigit tmb | 2022 |
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers | 2022 ASCO Annual Meeting | 2022 | 2022-asco-annual-meeting | pd-l1-ihc rnaseq | solid-tumors | ctla-4 lag3 pd-l1 tmb | 2022 |
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC | 2022 ASCO Annual Meeting | 2022 | 2022-asco-annual-meeting | pd-l1-ihc rnaseq | solid-tumors | pd-l1 | 2022 |
PD-L1 expression by RNA-sequencing and survival from pembrolizumab in non-small cell lung cancer (NSCLC) | American Association of Cancer Research 2022 | 2022 | american-association-of-cancer-research-2022 | pd-l1-ihc rnaseq | non-small-cell-lung-cancer | pd-l1 | 2022 |
Cancer testis antigen burden: pan-cancer distribution and survival implications | American Association of Cancer Research 2022 | 2022 | american-association-of-cancer-research-2022 | rnaseq | solid-tumors | ct-antigens | 2022 |
Checkpoint coexpression landscape in gastroesophageal adenocarcinoma | International Gastric Cancer Congress 2022 | 2022 | international-gastric-cancer-congress-2022 | rnaseq | solid-tumors | immune-profile tumor-immunogenic-signature tumor-inflammation | 2022 |
Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC | Journal of Thoracic Oncology - Clinical and Research Reports | 2021 | journal-of-thoracic-oncology-clinical-and-research-reports | rnaseq | non-small-cell-lung-cancer | bmi | 2021 |
Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma | Journal of Personalized Medicine | 2021 | journal-of-personalized-medicine | pd-l1-ihc rnaseq | gi-tumors | immune-profile | 2021 |
A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors | PLOS ONE | 2021 | plos-one | dna-seq msi rnaseq tmb | solid-tumors | analytical-validation | 2021 |
Molecular profiling of metastatic renal cell carcinoma treated with ipilimumab-nivolumab | International Kidney Cancer Symposium (2021 IKCS) | 2021 | international-kidney-cancer-symposium-2021-ikcs | pd-l1-ihc rnaseq | kidney | immune-profile pd-l1 | 2021 |
Immune and cancer testis antigen landscape in sarcoma | Connective Tissue Oncology Society (CTOS 2021) | 2021 | connective-tissue-oncology-society-ctos-2021 | pd-l1-ihc rnaseq | sarcoma | ct-antigens immune-profile pd-l1 | 2021 |
Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors | SITC’s 36th Annual Meeting | 2021 | sitcs-36th-annual-meeting | dna-seq ihc rnaseq tmb | solid-tumors | clinical-decision-making immune-profile | 2021 |
Cancer testis antigen burden: A novel predictive biomarker for immunotherapy in solid tumors | SITC’s 36th Annual Meeting | 2021 | sitcs-36th-annual-meeting | rnaseq | solid-tumors | ct-antigens | 2021 |
Novel immunotherapeutic targets in cancer of unknown primary (CUP) | SITC’s 36th Annual Meeting | 2021 | sitcs-36th-annual-meeting | dna-seq pd-l1-ihc rnaseq tmb | solid-tumors | clinical-decision-making immune-profile | 2021 |
Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project | Annals of Oncology | 2021 | annals-of-oncology | tmb | solid-tumors | tmb | 2021 |
Cancer/testis antigen expression landscape in gastroesophageal adenocarcinoma | ESMO 2021 | 2021 | esmo-2021 | rnaseq | gi-tumors solid-tumors | bmi ct-antigens | 2021 |
Diverse RNA expression patterns of T cell priming markers in various solid tumors and their clinical implication | ESMO 2021 | 2021 | esmo-2021 | dna-seq msi pd-l1-ihc | solid-tumors | pd-l1 tmb | 2021 |
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience | British Journal of Cancer | 2021 | british-journal-of-cancer | ocp | urothelial-carcinoma | fgfr | 2021 |
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response | Biomarker Research | 2021 | biomarker-research | ihc msi pd-l1-ihc rnaseq tmb | lung-cancer non-small-cell-lung-cancer | ct-antigens immune-profile infiltrated-tumors tumor-immunogenic-signature | 2021 |
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions | Genome Biology | 2021 | genome-biology | dna-seq | solid-tumors | analytical-validation comparator-study | 2021 |
Visceral Obesity Promotes Lung Cancer Progression – Towards Resolution of the Obesity Paradox in Lung Cancer | Journal of Thoracic Oncology | 2021 | journal-of-thoracic-oncology | rnaseq | lung-cancer non-small-cell-lung-cancer solid-tumors | immune-profile inflammation | 2021 |
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology | Nature Biotechnology | 2021 | nature-biotechnology | dna-seq | circulating-tumor-dna ctdna | ctdna predictive-algorithm validation | 2021 |
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors | Nature Communications | 2021 | nature-communications | dna-seq rnaseq | colorectal | immune-profile tmb | 2021 |
Immune profiling and immunotherapeutic targets in pancreatic cancer | Annals of Translational Medicine | 2021 | annals-of-translational-medicine | | pancreatic-cancer solid-tumors | immune-profile | 2021 |
Cancer-testis antigen detection by targeted RNA sequencing | 2020 AMP Annual Meeting | 2020 | 2020-amp-annual-meeting | rnaseq | solid-tumors | ct-antigens | 2020 |
Cancer testis antigen co-expression landscape in solid tumors | SITC's 35th Annual Meeting (2020) | 2020 | sitcs-35th-annual-meeting-2020 | rnaseq | solid-tumors | ct-antigens | 2020 |
PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer | SITC's 35th Annual Meeting (2020) | 2020 | sitcs-35th-annual-meeting-2020 | ihc rnaseq | non-small-cell-lung-cancer | pd-l1 | 2020 |
Complex markers of survival from pembrolizumab: The potential predictive role of tumor mutational burden (TMB) and KRAS | SITC's 35th Annual Meeting (2020) | 2020 | sitcs-35th-annual-meeting-2020 | dna-seq tmb | non-small-cell-lung-cancer | alk egfr kras stk11 tmb tp53 | 2020 |
Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice | Clinical Therapeutics | 2020 | clinical-therapeutics | | non-small-cell-lung-cancer | immune-profile | 2020 |
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients | OncoImmunology | 2020 | oncoimmunology | msi pd-l1-ihc rnaseq tmb | renal-cell-carcinoma | cell-proliferation | 2020 |
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity | OncoImmunology | 2020 | oncoimmunology | msi pd-l1-ihc rnaseq tmb | solid-tumors | immune-profile | 2020 |
Distinct pathways of DC-induced CD8+ T cell differentiation revealed by single-cell mRNA sequencing analysis | AACR Annual Meeting 2020 | 2020 | aacr-annual-meeting-2020 | rnaseq | immune-cells | immune-profile | 2020 |
Single-cell mRNA sequencing analysis of the synergistic impact of double-stranded RNA (dsRNA) and IFNa on human monocyte-derived macrophages | AACR Annual Meeting 2020 | 2020 | aacr-annual-meeting-2020 | rnaseq | immune-cells | immune-profile | 2020 |
Molecular characterization of advanced muscle invasive bladder cancer (MIBC): Comparison of low-input targeted RNA sequencing (RNAseq) strategies | 2020 Genitourinary Cancers Symposium | 2020 | 2020-genitourinary-cancers-symposium | rnaseq | bladder-cancer | comparator-study | 2020 |
Inflammation and cell proliferation signatures: Implications for response to immune checkpoint inhibition therapies | 2020 ASCO-SITC Clinical Immuno-Oncology Symposium | 2020 | 2020-asco-sitc-clinical-immuno-oncology-symposium | rnaseq | solid-tumors | cell-proliferation inflammation tumor-immunogenic-signature | 2020 |
Tumor inflammatory signature as a biomarker of response to immunotherapy in lung cancer | 2020 ASCO-SITC Clinical Immuno-Oncology Symposium | 2020 | 2020-asco-sitc-clinical-immuno-oncology-symposium | rnaseq | lung-cancer | inflammation tumor-immunogenic-signature | 2020 |
TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer | Frontiers in Immunology | 2020 | frontiers-in-immunology | tcrb | melanoma | ctla-4 tcr%ce%b2 | 2020 |
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay | Oncotarget | 2019 | oncotarget | msi | solid-tumors | analytical-validation | 2019 |
Unique Tumor Immune Microenvironments Of Potentially PD-L1/TGF-β Trap Responsive Tumors | SITC's 34th Annual Meeting (2019) | 2019 | sitcs-34th-annual-meeting-2019 | msi pd-l1-ihc rnaseq tmb | solid-tumors | bispecifics tme | 2019 |
CT Antigens are Frequently Expressed in Non-Inflamed Tumors | SITC's 34th Annual Meeting (2019) | 2019 | sitcs-34th-annual-meeting-2019 | msi pd-l1-ihc rnaseq tmb | solid-tumors | ct-antigens tme | 2019 |
Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing | Journal of Immunotherapy and Precision Oncology | 2019 | journal-of-immunotherapy-and-precision-oncology | tcrb | peripheral-blood-leukocytes | haplotype-analysis tcr%ce%b2 | 2019 |
Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC | Journal of Thoracic Oncology | 2019 | journal-of-thoracic-oncology | rnaseq | solid-tumors | bmi immune-profile metformin | 2019 |
Oncologist uptake of comprehensive genomic profile guided targeted therapy | Oncotarget | 2019 | oncotarget | ocp | solid-tumors | clinical-decision-making clinical-utility | 2019 |
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma | ASCO-SITC Clinical Immuno-Oncology Symposium - 2019 | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | msi pd-l1-ihc rnaseq tmb | renal-cell-carcinoma | cell-proliferation patient-response tumor-inflammation | 2019 |
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma (RCC) | ASCO-SITC Clinical Immuno-Oncology Symposium - 2019 | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | msi pd-l1-ihc rnaseq tmb | renal-cell-carcinoma | cell-proliferation patient-response tumor-inflammation | 2019 |
Tumor Mutational Burden (TMB): Assessment of Inter-and Intra-tumor heterogeneity | ASCO-SITC Clinical Immuno-Oncology Symposium - 2019 | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | tmb | solid-tumors | comparator-study specimen-characteristics validation | 2019 |
RNA-sequencing reveals immunotherapy targets in gynecological cancer | ASCO-SITC Clinical Immuno-Oncology Symposium - 2019 | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | msi pd-l1-ihc rnaseq tmb | gynocological-cancers | immune-profile immune-suppression | 2019 |
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients | Journal for ImmunoTherapy of Cancer | 2019 | journal-for-immunotherapy-of-cancer | msi pd-l1-ihc rnaseq tmb | non-small-cell-lung-cancer | cell-proliferation patient-survival | 2019 |
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors | Journal for ImmunoTherapy of Cancer | 2019 | journal-for-immunotherapy-of-cancer | pd-l1-ihc rnaseq | solid-tumors | comparator-study patient-response pd-l1 | 2019 |
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing | BMC Medical Informatics and Decision Making | 2019 | bmc-medical-informatics-and-decision-making | ocp | solid-tumors | clinical-decision-making clinical-utility | 2019 |
RNA-Expression Profiling Reveals Immunotherapy Targets in Sarcoma | Journal of Sarcoma Research | 2018 | journal-of-sarcoma-research | msi pd-l1-ihc rnaseq tmb | sarcoma | immune-profile myeloid-suppression | 2018 |
Identification of targets for prostate cancer immunotherapy | The Prostate | 2018 | the-prostate | msi pd-l1-ihc rnaseq tmb | prostate-cancer | immune-profile | 2018 |
Tumor mutational burden (TMB) ring study: Comparison of multiple targeted next-generation sequencing (NGS) platforms | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | tmb | solid-tumors | comparator-study tmb | 2018 |
Identifying major immune subsets of GI tumors for clinical purposes | SITC's 33rd Annual Meeting (2018) | 2018 | sitcs-33rd-annual-meeting-2018 | msi pd-l1-ihc rnaseq tmb | gi-tumors | immune-profile | 2018 |
Development of a next-generation sequencing-based microsatellite instability assay (MSI NGS) for solid tumor testing | SITC's 33rd Annual Meeting (2018) | 2018 | sitcs-33rd-annual-meeting-2018 | msi | solid-tumors | analytical-validation | 2018 |
Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-Small Cell Lung Cancer | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | pd-l1-ihc | non-small-cell-lung-cancer | cell-proliferation patient-survival | 2018 |
Combination immunotherapy selection for non-PD-1 axis driven tumors | 2018 ASCO Annual Meeting | 2018 | 2018-asco-annual-meeting | rnaseq | solid-tumors | immune-profile | 2018 |
Combination immunotherapy selection for PD-1 axis driven tumors | 2018 ASCO Annual Meeting | 2018 | 2018-asco-annual-meeting | rnaseq | solid-tumors | immune-profile | 2018 |
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab | OncoImmunology | 2018 | oncoimmunology | msi pd-l1-ihc rnaseq tmb | urothelial-carcinoma | immune-profile patient-response pd-l2 | 2018 |
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden | Journal for ImmunoTherapy of Cancer | 2018 | journal-for-immunotherapy-of-cancer | msi pd-l1-ihc rnaseq tmb | melanoma | patient-survival tumor-inflammation | 2018 |
Chemokine expression signatures in infiltrated vs non-infiltrated tumors | AACR Annual Meeting 2018 | 2018 | aacr-annual-meeting-2018 | msi pd-l1-ihc rnaseq tmb | solid-tumors | chemokines infiltrated-tumors tumor-infiltrating-lymphocytes | 2018 |
PD-L1 driven excluded phenotype in melanoma | AACR Annual Meeting 2018 | 2018 | aacr-annual-meeting-2018 | msi pd-l1-ihc rnaseq tmb | melanoma | cd8 excluded-phenotype | 2018 |
Predicting Response: PD-L1 Biomarker Testing by IHC and RNA-seq | AACR Annual Meeting 2018 | 2018 | aacr-annual-meeting-2018 | msi pd-l1-ihc rnaseq tmb | solid-tumors | patient-response pd-l1 | 2018 |
Immune Deserts: Low CD8 Gene Expression Correlates with Non-response to Checkpoint Inhibition | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | msi pd-l1-ihc rnaseq tmb | solid-tumors | cd8 patient-response | 2018 |
Comprehensive Immune and Mutational Profile of Melanoma | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | oa | melanoma | immune-profile mutational-profile | 2018 |
CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in Melanoma | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | oa | melanoma | ctla4 patient-response | 2018 |
Lung Cancer Mutational Profile Correlates with Immune Profile | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | msi pd-l1-ihc rnaseq tmb | lung-cancer | immune-profile mutational-profile | 2018 |
Overexpression of Immunotherapeutic Targets in the Immune Desert Phenotype | SITC's 32nd Annual Meeting (2017) | 2017 | sitcs-32nd-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | immune-desert immune-profile | 2017 |
Comprehensive Characterization of Solid Tumor Immune Profiles for Precision Immunotherapy Using Immune Report Card℠ | SITC's 32nd Annual Meeting (2017) | 2017 | sitcs-32nd-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | immune-profile | 2017 |
The Immune-Excluded Phenotype Beyond Colorectal Cancer | SITC's 32nd Annual Meeting (2017) | 2017 | sitcs-32nd-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | cd8 excluded-phenotype | 2017 |
Secondary Immunotherapeutic Targets In Inflamed Tumors | SITC's 32nd Annual Meeting (2017) | 2017 | sitcs-32nd-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | immune-profile tumor-inflammation | 2017 |
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors | The Journal of Molecular Diagnostics | 2017 | the-journal-of-molecular-diagnostics | msi pd-l1-ihc rnaseq tmb | solid-tumors | analytical-validation | 2017 |
Algorithmic Prediction of Response to Checkpoint Inhibitors | 2017 ASCO Annual Meeting | 2017 | 2017-asco-annual-meeting | rnaseq | solid-tumors | patient-response predicitve-algorithm | 2017 |
The Inflamed Phenotype in PD-L1 Negative Melanoma and Response to Checkpoint Inhibitors | Immunology 2017 | 2017 | immunology-2017 | msi pd-l1-ihc rnaseq tmb | melanoma | patient-response tumor-inflammation | 2017 |
The Inflamed Phenotype in PD-L1 Negative NSCLC and Response to Checkpoint Inhibitors | Immunology 2017 | 2017 | immunology-2017 | msi pd-l1-ihc rnaseq tmb | non-small-cell-lung-cancer | patient-response tumor-inflammation | 2017 |
Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification | AACR Annual Meeting 2017 | 2017 | aacr-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | specimen-characteristics validation | 2017 |
NGS reveals specimen characteristics have minimal impact on immune gene expression signature | AACR Annual Meeting 2017 | 2017 | aacr-annual-meeting-2017 | rnaseq | | specimen-characteristics validation | 2017 |
Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient | AACR Annual Meeting 2017 | 2017 | aacr-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | specimen-characteristics validation | 2017 |
Analytical Validation of an Immune Response Assay for Classifying Solid Tumors | 2017 ASCO Annual Meeting | 2017 | 2017-asco-annual-meeting | msi pd-l1-ihc rnaseq tmb | | analytical-validation | 2017 |
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing | Oncotarget | 2016 | oncotarget | msi pd-l1-ihc rnaseq tmb | solid-tumors | comparator-study specimen-characteristics validation | 2016 |
An Algorithmic Approach to Cancer Immune Profiling | SITC's 31st Annual Meeting (2016) | 2016 | sitcs-31st-annual-meeting-2016 | msi pd-l1-ihc rnaseq tmb | solid-tumors | patient-response predicitve-algorithm | 2016 |
Validation of a Custom RNA-Seq Approach to Cancer Immune Profiling | SITC's 31st Annual Meeting (2016) | 2016 | sitcs-31st-annual-meeting-2016 | msi pd-l1-ihc rnaseq tmb | solid-tumors | comparator-study specimen-characteristics validation | 2016 |